Date: 2015-01-08
Type of information: Licensing agreement
Compound: Monofer®
Company: Helsinn (Switzerland) Pharmacosmos (Denmark)
Therapeutic area:
Type agreement: licensing development commercialisation
Action mechanism: Monofer® (10% iron isomaltoside 1000) is an iron-carbohydrate complex for intravenous administration. Monofer® is already marketed in more than 30 countries, primarily in Europe, for the treatment of iron deficiency anemia. Monofer® is under development in the rest of the world, including North America and Japan. It is believed that the structure of Monofer® differentiates it from other intravenous iron replacement therapies, allowing the possibility to administer high iron doses in one visit over a short period of time for the benefit and convenience of patients and healthcare professionals. Monofer® is manufactured by Pharmacosmos, Denmark.
Disease: iron deficiency anemia
Details: * On January 8, 2015, Helsinn Group and Pharmacosmos jointly announce that they have entered into an agreement for the exclusive US commercialization rights to Monofer®, an intravenous iron replacement therapy under development for the treatment of Iron Deficiency Anemia. Helsinn has obtained the exclusive rights to commercialize Monofer® and any other iron isomaltoside 1000 products developed by Pharmacosmos in the US.
Financial terms: Pharmacosmos is eligible for milestone payments of up to $ 130 million for MonoferÒ in iron deficiency anemia in the US. In addition, Pharmacosmos will be eligible to receive further payments for the manufacture and supply of MonoferÒ to Helsinn in the US.
Latest news:
